Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Resurrected Flibanserin Filing Tests FDA Position On Female Sexual Desire Disorders

Executive Summary

With a decision by FDA on a new filing for flibanserin possible by the fall, Sprout hopes to gain the first U.S. approval for treating women with low sexual desire. Meanwhile, Palatin forges on to Phase III with its female sexual desire disorder drug bremelanotide after discussing endpoints with FDA.

Advertisement

Related Content

Women’s Intuition: What Approval Of Sprout’s Addyi Means For Sponsors
Sprout’s Low Libido Drug Flibanserin Going To FDA Advisory Panel
Timing Better For Sprout’s Latest Shot At First Female Sex Desire Drug
Timing Better For Sprout’s Latest Shot At First Female Sex Desire Drug
A New Dawn For Female Sex Dysfunction Drugs? FDA Meeting Cheers Sponsors
Sprout’s Female Desire Drug: Size Of Safety Studies Doesn’t Matter To FDA
BioSante LibiGel Study Design Changes Could Yield Better Results For Sexual Dysfunction
Emerging Companies Look To Niche Hot Spots For Partnering
BI Drops Flibanserin; BioSante Gets Excited
Flibanserin Fails To Improve Sexual Desire, FDA Advisory Committee Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055485

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel